MIST - Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm | Benzinga
BOSTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Milestone Pharmaceuticals, Inc. (NASDAQ:MIST) for potential securities law violations. Investors who have lost money in their Milestone Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/mist.
What is this all about?
Before the market opened on December 26, 2023, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File ("RFT") letter from the U.S. Food and Drug Administration ("FDA") for its recently submitted New Drug Application for its lead candidate, Etripamil. In the RFT, the FDA noted that Milestone had not ...